Privately-held biopharma PanOptica said today that it raised $11 million in a Series B round to fund the clinical advancement of its anti-VEGF eye drop for the treatment of neovascular eye diseases. The funding, led by Third Rock Ventures and SV Health Investors, will support a Phase I/II study of a new formulation of PAN-90806 […]
